Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mosunetuzumab Consolidation Therapy After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma
NCT05412290Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2022
- Primary completion
- Sep 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mosunetuzumab in B cell lymphoma, diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL) and 2 more, sponsored by Washington University School of Medicine. Primary endpoints: Frequencies and grades of treatment-emergent adverse events at 7 months, Rate of treatment discontinuation due to treatment-emergent adverse events at 7 months and 1 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
mosunetuzumab
03
Conditions
B cell lymphomadiffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)transformed lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05412290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05412290.